GlassScriptPhysician profile
Shannon S Greer
NPI 1811979917
$93,131.82
in general payments reported to CMS, 2019-2025
29 companies · $6,402 in 2025
The $6,402 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $549 · 2021: $469 · 2022: $39K · 2023: $32K · 2024: $14K · 2025: $6,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Travel and Lodging: $7,710 · Food and Beverage: $4,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,000.00 |
| Travel and Lodging | $7,710.34 |
| Food and Beverage | $4,044.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $89,163.02 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,375.01 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Paratek Pharmaceuticals, INC. | $240.95 | 2022-2023 | Nuzyra |
| Alnylam Pharmaceuticals INC. | $201.89 | 2023-2024 | Amvuttra, Onpattro |
| Janssen Pharmaceuticals, INC | $194.45 | 2019-2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $193.79 | 2019-2023 | Evkeeza |
| Novartis Pharmaceuticals Corporation | $180.88 | 2021-2025 | |
| Amarin Pharma, INC. | $167.86 | 2019-2021 | |
| Spinal Simplicity, LLC | $149.89 | 2024 | Ha Minuteman G3-R |
| Sumitomo Pharma America, INC. | $147.40 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $134.48 | 2019-2025 | Gardasil 9, Capvaxive |
| Foundation Fusion Solutions, LLC | $129.35 | 2024 | |
| Lilly USA, LLC | $110.01 | 2020-2025 | Mounjaro, Kisunla |
| Boston Scientific Corporation | $90.36 | 2023 | |
| Novo Nordisk INC | $88.81 | 2019-2024 | Ozempic, Rybelsus |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinefrontier, INC. | $72.64 | 2025 | Inspan, Nanofuse, Facetfuse |
| Medtronic, INC. | $69.23 | 2021 | |
| Pfizer INC. | $67.71 | 2020-2023 | |
| Merz North America, INC. | $66.74 | 2023-2025 | Xeomin |
| Kowa Pharmaceuticals America, INC. | $54.86 | 2019-2020 | |
| Antares Pharma, INC. | $46.08 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Abbvie INC. | $40.73 | 2021-2024 | |
| Ge Healthcare | $28.70 | 2019 | |
| Nevro Corp. | $28.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.58 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.72 | 2021 | |
| Allergan, INC. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.